Bridge Biotherapeutics to Present at the 2023 BIO International Convention
2023-05-29
并购
SEONGNAM, South Korea and CAMBRIDGE, Mass., May 29, 2023 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, is scheduled to give a company presentation on Tuesday, June 6 at the 2023 BIO International Convention taking place in Boston, Massachusetts, between June 5 - 8, 2023.
Pavel Printsev, Director of Business Development, will provide an up-to-date company overview as well as an introduction to its clinical-stage assets:
Oncology: BBT-176 and BBT-207 (Fourth-generation EGFR TKIs for non-small cell lung cancer active against C797S resistance mutations)
Pulmonology: BBT-877 (Autotaxin inhibitorAutotaxin inhibitor for idiopathic pulmonary fibrosis)
Earlier this year, the company announced its acquisition of a diagnostics company with a novel biosensing technology. The company presentation is expected to include an introduction to the newly acquired biosensing technology and commercial prospects.
"We are pleased to share the progress of clinical assets as well as new business activities through an in-person presentation at this year's BIO International conference, following last year's event. We look forward to advancing our novel research and development pipeline with a strong focus on oncology and pulmonology," stated Pavel Printsev, Director of Business Development of Bridge Biotherapeutics.
To learn more about this session, please visit the events page on our website at https://bit.ly/3lEGVDY.
Date & Time: Tuesday, June 6th, 2023, 3:15 PM (ET)
Place: Room 104B
Therapeutic category: Multiple Therapeutics
About Bridge Biotherapeutics
Bridge Biotherapeutics Inc., based in the Republic of Korea and the U.S., is a publicly-traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs, including ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitorPellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitorautotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), BBT-176 and BBT-207, potent targeted cancer therapies for non-small cell lung cancer (NSCLC) with EGFR C797S mutations. Learn more at https://www.bridgebiorx.com/en/.
SOURCE Bridge Biotherapeutics, Inc.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。